We selected two samples from two distinct patients, each with a tumor population characterized by a distinct driver mutation (TP53 p.C207Y vs. ARID1A splice) that was orthogonally validated by bulk WES as well as independent Tapestri runs. This evidence concerns the gene TP53 and neoplasm.